Mecamylamine is a nicotinic acetylcholine receptor (nAChR) antagonist; research by Zhu et al. (2003) showed that mecamylamine could reverse the increase in VEGF and circulating endothelial progenitor cells (EPC) caused by secondhand smoke, thereby inhibiting tumor growth and angiogenesis. Here, VEGFA is linked to neoplasm.